An Open-Label, Randomised, Multi-Centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months [for extension study, see profile 700008605].

Trial Profile

An Open-Label, Randomised, Multi-Centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months [for extension study, see profile 700008605].

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Aug 2011 New source identified and integrated (German Clinical Trials Register; DRKS00000024, UKF000001).
    • 25 Aug 2011 New source identified and integrated (German Clinical Trials Register; DRKS00000024, UKF000001).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top